

Food and Drug Administration Rockville MD 20857

June 18, 2013

FILE COPY

Nuo Wang, Ph.D. Managing Member SALUS PHARMA, LLC 11 Deer Park Drive Unit 120 Monmouth Junction, NJ 08852

Dear Dr. Wang:

Your petition to the Food and Drug Administration requesting to determine whether Zefazone (cefmetazole sodium) injection, EQ 1gm base/vial and EQ 2 GM base/vial have been voluntarily withdrawn from sale for safety or efficacy reasons, was received by this office on 06/18/2013. It was assigned docket number FDA-2013-P-0768/CP1, and it was filed on 06/18/2013. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Gloria Ortega

Administrative Proceedings Officer Division of Dockets Management

FDA/Office of the Executive Secretariat (OES)